Nuclear medicine and biology最新文献

{"title":"Myocardial kinetics of [11C]β-hydroxybutyrate in healthy pigs: Comparison of positron emission tomography imaging vs. arteriovenous balance methods","authors":"Mette Louise Gram Kjærulff ,&nbsp;Mie Ringgaard Dollerup ,&nbsp;Aage Kristian Olsen Alstrup ,&nbsp;Nigopan Gopalasingam ,&nbsp;Lars Poulsen Tolbod ,&nbsp;Ole Lajord Munk ,&nbsp;Lars Christian Gormsen ,&nbsp;Erik Nguyen Nielsen","doi":"10.1016/j.nucmedbio.2025.109053","DOIUrl":"10.1016/j.nucmedbio.2025.109053","url":null,"abstract":"<div><h3>Background</h3><div>Accurate assessment of myocardial ketone uptake and oxidation is essential for understanding cardiac metabolism. This study aims to validate positron emission tomography (PET) imaging as a non-invasive method for quantifying myocardial ketone metabolism, using the invasive arteriovenous (AV) balance method as reference.</div></div><div><h3>Methods</h3><div>Myocardial ketone uptake was assessed using [¹¹C]β-hydroxybutyrate ([¹¹C]OHB) PET imaging in a porcine model. Blood samples were collected from arterial and coronary sinus sites, and kinetic parameters were calculated to evaluate the relationship between PET-derived and AV balance-derived measurements. Myocardial perfusion was assessed using [¹⁵O]water PET scans. The procedures were conducted during a graded infusion of ketone salt.</div></div><div><h3>Results</h3><div>A strong positive correlation between PET-derived and AV balance-derived measurements of myocardial OHB uptake was observed (<em>r</em> = 0.97; <em>p</em> &lt; 0.0001), indicating that [¹¹C]OHB PET imaging can reliably assess myocardial ketone metabolism. The correlation between the rate constant <em>k</em>₂ and the [¹¹C]CO₂ fraction in coronary sinus blood was near-significant, moderate and positive (<em>r</em> = 0.71; <em>p</em> = 0.08), suggesting potential for <em>k</em>₂ as a marker of myocardial ketone oxidation.</div></div><div><h3>Conclusion</h3><div>[¹¹C]OHB PET imaging is a non-invasive tool for assessing myocardial ketone metabolism, providing valuable insights into ketone uptake and oxidation in vivo, with potential for extrapolation to human data.</div></div>","PeriodicalId":19363,"journal":{"name":"Nuclear medicine and biology","volume":"148 ","pages":"Article 109053"},"PeriodicalIF":3.6,"publicationDate":"2025-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144679512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ImmunoPET for mesothelin positive tissues using bio-orthogonal in-vivo click chemistry","authors":"Edwin C. Pratt ,&nbsp;Komal Mandleywala ,&nbsp;David Bauer ,&nbsp;Alexander Bolaender ,&nbsp;Grace Chao ,&nbsp;Mark A. Castanares ,&nbsp;Emily C. Collins ,&nbsp;Jason S. Lewis","doi":"10.1016/j.nucmedbio.2025.109051","DOIUrl":"10.1016/j.nucmedbio.2025.109051","url":null,"abstract":"<div><div>Mesothelin is a membrane bound antigen overexpressed in a wide array of cancers including ovarian, pancreatic, lung, and triple negative breast cancers. Here a full-length IgG antibody developed against mesothelin, called MESO-HSS1 was conjugated for immunoPET imaging and assessed in-vivo in a H956 mesothelin positive model. Furthermore, random lysine conjugation as well as a site selective conjugation method were compared in two pretargeting models for overall tumor uptake alongside non target organs and tumor to organ ratios. Overall, [⁸⁹Zr]Zr-DFO-MESO-HSS1 was found to be a suitable immunoPET radiotracer for the detection of the mesothelin low cancer line H596 as early as 24 h post injection with up to 20.1 % injected dose per gram by 144 h. Furthermore, in pretargeted models, lysine conjugation of TCO-Lys-MESO-HSS1 with [⁶⁴Cu]Cu-Sar-Tz yielded the highest tumor uptake at 2.6 % injected dose per gram at 24 h. Imaging 4 h post injection of [¹⁸F]F-Al-NOTA-PEG₇-Tz however was best with TCO-SS-MESO-HSS1 with improved tumor to organ ratios as expected from site selective modifications. High tumor to pancreas ratios suggests mesothelin imaging could be a highly effective diagnostic for pancreatic cancer identification. Together these data show MESO-HSS1 as a direct immunoPET or pretargeting agent as a viable immunoPET system for imaging mesothelin positive cancers.</div></div>","PeriodicalId":19363,"journal":{"name":"Nuclear medicine and biology","volume":"148 ","pages":"Article 109051"},"PeriodicalIF":3.6,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144670371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Brain metabolic and behavioral alterations in a Down syndrome model","authors":"Larissa Estessi de Souza ,&nbsp;Chiara Maria Righini ,&nbsp;Dimitri Brigide de Almeida Mantovani ,&nbsp;Manuella Penido Silva ,&nbsp;Gabriela Lazzarotto ,&nbsp;Christian Limberger ,&nbsp;Carlos Alberto Buchpiguel ,&nbsp;Eduardo Rigon Zimmer ,&nbsp;Caroline Cristiano Real ,&nbsp;Lidia Emmanuela Wiazowski Spelta ,&nbsp;Daniele de Paula Faria","doi":"10.1016/j.nucmedbio.2025.109052","DOIUrl":"10.1016/j.nucmedbio.2025.109052","url":null,"abstract":"<div><h3>Purpose</h3><div>This work aimed to monitor the Down Syndrome Ts65Dn animal model across lifespan to detect time-dependent in vivo molecular alterations that may be associated with neurodegeneration and neuroinflammation in this model.</div></div><div><h3>Methods</h3><div>Euploid and trisomic Ts65Dn animals were longitudinally evaluated at 2, 5, 14, 20, and 24 months of age using brain [¹⁸F]FDG PET and behavioral tasks (open field and novel object recognition). VOI-based SUV, Voxel-wise, and metabolic network analyses were performed. Cross-sectional post-mortem brain analysis was carried out at the same ages to measure neuronal loss and microglia activation.</div></div><div><h3>Results</h3><div>There was an increase in brain metabolism at 14 months of age in both genotypes, when compared to the other analyzed ages. [¹⁸F]FDG uptake correlated with microglia activation measured by Iba-1 immunohistochemistry, suggesting that the tracer increased due to a neuroinflammation process. In addition, metabolic network analysis showed more accentuated desynchronization in [¹⁸F]FDG uptake in older trisomic mice, than in euploid animals. At 24 months of age, trisomic animals presented a worse long-term memory recognition index and an age-dependent decrease in NeuN staining, which was not associated with [¹⁸F]FDG uptake.</div></div><div><h3>Conclusions</h3><div>This is the first study to monitor the Ts65Dn mouse model throughout life - from 2 to 24 months of age – using [¹⁸F]FDG PET imaging and metabolic network analysis. Our results collectively highlight that trisomic mice experience early disruption in brain network organization, likely contributing to functional impairments associated with aging, neurodegeneration, and neuroinflammation.</div></div>","PeriodicalId":19363,"journal":{"name":"Nuclear medicine and biology","volume":"148 ","pages":"Article 109052"},"PeriodicalIF":3.6,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144656179","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ubiquicidin derived peptides for infection imaging","authors":"Anoushka Sachdeva ,&nbsp;Jyotsna Bhatt Mitra ,&nbsp;Archana Mukherjee","doi":"10.1016/j.nucmedbio.2025.109049","DOIUrl":"10.1016/j.nucmedbio.2025.109049","url":null,"abstract":"<div><div>Ubiquicidin (UBI), a 59-amino-acid protein, demonstrates potent antimicrobial activity against various microorganisms and has been proposed as a potential antimicrobial agent. Similar to other antimicrobial proteins and peptides (AMPs), UBI is rich in positively charged residues, which enable it to interact with bacterial membranes through their negatively charged phospholipids. Since the 1990s, radiolabelled ubiquicidin derivatives, particularly [^99mTc] Tc-UBI (29–41), have been developed and extensively evaluated as single-photon emission computed tomography (SPECT) tracers for imaging focal infections. Ability of radiolabelled ubiquicidin fragments to distinguish between sterile inflammation and infection further underscores its potential in imaging occult infections. With the emergence of ⁶⁸Ga based radiopharmaceuticals, the development of positron emission tomography (PET) tracers derived from ubiquicidin fragments has gained significant interest. Furthermore, advancements have been made in designing peptide-covalent probe hybrids and fluorophore based ubiquicidin derivatives for imaging focal infections. So far, [⁶⁸Ga]Ga-UBI(29–41) has shown exceptional promise. However, multicentre clinical trials are essential to validate its efficacy and establish it as an ideal radiopharmaceutical for imaging bacterial infections.</div></div>","PeriodicalId":19363,"journal":{"name":"Nuclear medicine and biology","volume":"146 ","pages":"Article 109049"},"PeriodicalIF":3.6,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144524312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unravelling the role of L- and D- alanine in prostate cancer: a Positron Emission Tomography study in a genetic mouse model","authors":"Pilar Castellnou ,&nbsp;María Gómez-Martínez ,&nbsp;Vanessa Gómez-Vallejo ,&nbsp;Zuriñe Baz ,&nbsp;Fernando López-Gallego ,&nbsp;Ivana Rondon-Lorefice ,&nbsp;Amaia Zabala-Letona ,&nbsp;Alex J. Poot ,&nbsp;Isabel Mendizabal ,&nbsp;Arkaitz Carracedo ,&nbsp;Luka Rejc ,&nbsp;Jordi Llop","doi":"10.1016/j.nucmedbio.2025.109048","DOIUrl":"10.1016/j.nucmedbio.2025.109048","url":null,"abstract":"<div><h3>Introduction</h3><div>Cancer cells often exhibit aberrant cellular metabolism, with a common characteristic being their reliance on anaerobic glucose utilization. Prostate cancer (PC), however, displays unique metabolic profiles that extend beyond glycolysis, notably incorporating amino acid metabolism. This divergence in metabolic patterns opens potential avenues for targeted therapeutic strategies using D-amino acids. In this work, we investigated the biodistribution and tumour accumulation of D- and L-[<em>methyl</em>-¹¹C]alanine using positron emission tomography (PET) imaging in a genetic mouse model of prostate cancer.</div></div><div><h3>Methods</h3><div>D- and L-[<em>methyl</em>-¹¹C]alanine were synthesized according to established protocols. Conditional PTEN knockout mice (<em>n</em> = 6) were used as a model for prostate cancer. Dynamic PET-CT scans were performed for 60 min immediately following intravenous administration of the radiolabelled amino acids at the ages of 4 and 7 months. PET images were reconstructed, and volumes of interest (VOIs) were delineated in major organs, including the prostate and bladder. Dynamic time-activity curves (TACs) were analysed in terms of Standardized Uptake Values (SUV). After imaging, samples of the reproductive system were collected for static PET-CT imaging and subsequent histological analysis.</div></div><div><h3>Results and discussion</h3><div>L- and D-[<em>methyl</em>-¹¹C]alanine were synthesized with good radiochemical yields and high enantiomeric excess using enantioselective alkylation with [¹¹C]methyl iodide in the presence of a chiral phase transfer catalysts. PET imaging of a genetic faithful mouse model of prostate cancer demonstrated that D-[<em>methyl</em>-¹¹C]alanine exhibited faster blood clearance, higher age-dependent kidney retention, and greater prostate lesion uptake at 7 months compared to L-[<em>methyl</em>-¹¹C]alanine. Histological analysis confirmed malignant lesions in the prostate of PTEN knockout mice, corroborating the PET imaging findings.</div></div><div><h3>Conclusions</h3><div>Our study offers valuable insights into the metabolic landscape of prostate cancer using a genetic mouse model that closely mimics human disease pathogenesis. The significantly greater accumulation of D-[<em>methyl</em>-¹¹C]alanine compared to its L-enantiomer underscores the potential of D-amino acids as biomarkers, and their potential use to interfere with cancer cell metabolism.</div></div>","PeriodicalId":19363,"journal":{"name":"Nuclear medicine and biology","volume":"148 ","pages":"Article 109048"},"PeriodicalIF":3.6,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144597308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quantification of 89Zr-immunoPET: Methodological considerations","authors":"Philipp Mohr ,&nbsp;Joyce van Sluis ,&nbsp;Adrienne H. Brouwers ,&nbsp;Marjolijn N. Lub-de Hooge ,&nbsp;Zekai Li ,&nbsp;Claudia A.J. van Winkel ,&nbsp;Adriaan A. Lammertsma ,&nbsp;Charalampos Tsoumpas","doi":"10.1016/j.nucmedbio.2025.109050","DOIUrl":"10.1016/j.nucmedbio.2025.109050","url":null,"abstract":"<div><h3>Purpose</h3><div>Clinical ⁸⁹Zr-immunoPET relies on semi-quantitative metrics, such as standardised uptake values (SUV) from static imaging at delayed time points. However, SUV can misinterpret target engagement as it ignores plasma and tissue kinetics. Kinetic modelling, common for shorter-lived tracers, is rarely applied to ⁸⁹Zr-labelled monoclonal antibodies (mAbs) due to slow kinetics. This study characterises ⁸⁹Zr-immunoPET kinetics using a two-tissue compartment model, identifies factors affecting tracer uptake, and assesses the validity of semi-quantitative metrics.</div></div><div><h3>Procedures</h3><div>Realistic plasma input functions with different clearance rates, representing variable mAb kinetics and cold mAb doses, were derived from previous studies. Realistic ranges for kinetic rate constants and blood volume fractions were estimated based on literature. Each parameter was varied to assess its effect on ⁸⁹Zr-immunoPET time-activity curves and Patlak analysis. SUV and target-to-plasma ratios (TPR) at delayed time points were compared with Patlak net irreversible rate of uptake (<em>K</em>_<em>i</em>).</div></div><div><h3>Results</h3><div>Fast plasma kinetics resulted in small but specific uptake, while slow kinetics produced higher signals with larger nonspecific contributions. SUV and <em>K</em>_<em>i</em> were driven by tracer delivery (<em>K</em>_<em>1</em>) and residualisation upon binding (<em>k</em>_<em>3</em>), depending on the scenario. Within groups with limited variations in plasma clearance, semi-quantitative metrics correlated well with <em>K</em>_<em>i</em>. For slow kinetics, where nonspecific uptake contributes more prominently, TPR performed better than SUV. However, despite good agreement in general, linear fits between semi-quantitative metrics and <em>K</em>_<em>i</em> showed notable variability, indicating their limited reliability as surrogates for <em>K</em>_<em>i</em>. Between groups with large differences in plasma clearance, only normalisation by the integral of the plasma input function, as in Patlak analysis, enabled accurate interpretation.</div></div><div><h3>Conclusions</h3><div>Patlak analysis accounts for plasma kinetics and reversible signals, enabling more accurate interpretation of ⁸⁹Zr-immunoPET data than SUV. Wider use of kinetic modelling could enhance quantitative accuracy, support reinterpretation of past studies, and guide future study design.</div></div>","PeriodicalId":19363,"journal":{"name":"Nuclear medicine and biology","volume":"148 ","pages":"Article 109050"},"PeriodicalIF":3.6,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144518942","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “radiation dosimetry of the 18 kDa translocator protein ligand [18F]PBR111 in humans” [nuclear medicine and biology, 144–145 (2025); 109,011]","authors":"Benjamin B. Tournier ,&nbsp;Zahra Mansouri ,&nbsp;Yazdan Salimi ,&nbsp;Kelly Ceyzériat ,&nbsp;Gregory Mathoux ,&nbsp;Hélène Richard-Lepouriel ,&nbsp;Daniele Zullino ,&nbsp;Frédéric Bois ,&nbsp;Habib Zaidi ,&nbsp;Valentina Garibotto ,&nbsp;Stergios Tsartsalis ,&nbsp;Philippe Millet","doi":"10.1016/j.nucmedbio.2025.109047","DOIUrl":"10.1016/j.nucmedbio.2025.109047","url":null,"abstract":"","PeriodicalId":19363,"journal":{"name":"Nuclear medicine and biology","volume":"146 ","pages":"Article 109047"},"PeriodicalIF":3.6,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144364417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[18F]BCPP-BF-PET as an imaging tool for mitochondrial dysfunction in diabetic pancreatopathy and nephrotoxicity","authors":"Yuki Tomonari,&nbsp;Masakatsu Kanazawa,&nbsp;Shingo Nishiyama,&nbsp;Hiroyuki Ohba,&nbsp;Hideo Tsukada","doi":"10.1016/j.nucmedbio.2025.109046","DOIUrl":"10.1016/j.nucmedbio.2025.109046","url":null,"abstract":"<div><h3>Purpose</h3><div>[¹⁸F]BCPP-BF-PET imaging of mitochondrial complex I was validated as a biomarker of hyperglycaemia- and hyperlipidaemia-induced pancreatic and renal dysfunction in a type 2 diabetes mellitus (T2DM) animal model.</div></div><div><h3>Methods</h3><div>Male Zucker diabetic fatty (ZDF) (Fatty) rats as a T2DM model and lean ZDF (Lean) rats as controls were subjected to [¹⁸F]BCPP-BF-PET imaging at 5, 8, 16, and 26 weeks of age. Blood biochemical parameters were assessed at all ages, and the kidney and pancreas were dissected after PET measurement for morphological assessments at 16 and 26 weeks of age.</div></div><div><h3>Results</h3><div>Blood insulin and triglyceride levels were elevated in Fatty rats at 5 weeks of age and peaked at 8 weeks, followed by an increase in blood glucose and urea nitrogen levels at 16 weeks and thereafter. [¹⁸F]BCPP-BF uptake by the pancreas and kidneys was lower in Fatty rats than in Lean rats after 5 and 8 weeks of age, and thereafter. Pancreatic [¹⁸F]BCPP-BF uptake was inversely correlated with blood glucose and triglyceride levels as early as 5 weeks of age. In the pancreatic islets, a lower density of insulin-positive cells was detected in Fatty rats at 16 weeks of age, which was positively correlated with pancreatic [¹⁸F]BCPP-BF uptake. Renal [¹⁸F]BCPP-BF uptake and blood urea nitrogen indicated inverse correlations at 8 weeks of age and older, and the uptake and fibrotic areas revealed an inverse correlation at 16 weeks of age.</div></div><div><h3>Conclusion</h3><div>This study demonstrates the applicability of [¹⁸F]BCPP-BF-PET as a non-invasive biomarker for diagnosing hyperglycaemia- and hyperlipidaemia-induced pancreatic and renal damage in T2DM in the early phase of diabetes.</div></div>","PeriodicalId":19363,"journal":{"name":"Nuclear medicine and biology","volume":"146 ","pages":"Article 109046"},"PeriodicalIF":3.6,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144364489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Theranostic nanoparticles: Investigation of superparamagnetic iron oxide nanoparticles intrinsically labeled with Zirconium-89 and Actinium-225","authors":"George Diehl ,&nbsp;Zane G. Archibald ,&nbsp;Katherine Gingrich ,&nbsp;Aria T. Ballance ,&nbsp;Brandon Buckway ,&nbsp;Jennifer S. Shumaker-Parry ,&nbsp;Jeffrey T. Yap ,&nbsp;Ilya Zharov ,&nbsp;Tara Mastren","doi":"10.1016/j.nucmedbio.2025.109045","DOIUrl":"10.1016/j.nucmedbio.2025.109045","url":null,"abstract":"<div><div>Superparamagnetic iron oxide nanoparticles (SPIONs) are of interest for use as drug delivery vehicles due to their magnetic properties, tunable surface chemistry, and potential for use in magnetic resonance imaging and hyperthermia studies. Additionally, their high affinity for metals allows for radiolabeling radiometals for nuclear medicine applications like nano-theranostics. Herein, we report the synthesis of ²²⁵Ac-labeled and ⁸⁹Zr-labeled PEG-SPIONs. Actinium-225 showed preferential leaching during surface modification compared to zirconium-89, suggesting that it was predominantly bound in surface sites, while zirconium-89 was located at the internal lattice sites. The biodistribution of unmodified ⁸⁹Zr-labeled SPIONs and surface-modified ⁸⁹Zr-labeled PEG-SPIONs were compared using PET/MRI which showed rapid blood clearance due to liver uptake. Overall, the reported nanoparticles are promising for applications in targeted alpha therapy.</div></div>","PeriodicalId":19363,"journal":{"name":"Nuclear medicine and biology","volume":"146 ","pages":"Article 109045"},"PeriodicalIF":3.6,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144470079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiobiological effect of alpha particles. The scientific basis of targeted alpha-particle therapy","authors":"Pedro Cruz-Nova ,&nbsp;Maydelid Trujillo-Nolasco ,&nbsp;Liliana Aranda-Lara ,&nbsp;Guillermina Ferro-Flores ,&nbsp;Blanca Ocampo-García","doi":"10.1016/j.nucmedbio.2025.109044","DOIUrl":"10.1016/j.nucmedbio.2025.109044","url":null,"abstract":"<div><div>Targeted alpha therapy (TAT) uses alpha-emitting radionuclides to deliver high-energy radiation directly to a specific biological target. TAT has shown promising results in the treatment of advanced metastatic disease and has demonstrated greater efficacy than beta radiation in inducing apoptosis, mutations, carcinogenesis, chromosomal aberrations, and chromosomal instability. The biological effects of alpha particle radiation are associated with the high energy delivered over short distances, producing high levels of reactive oxygen and nitrogen species. Likewise, alpha particle radiation induces more mutations per median lethal dose compared to beta particles and promotes the accumulation of substitutions and indels. Identification of novel early response genes to alpha particles is critical for understanding the molecular mechanisms underlying genomic damage, cell death, and potentially latent malignant transformation.</div><div>This review provides an overview of the biological effects of alpha particle exposure, with the aim of enhancing the understanding, research, and development of alpha-emitter-based radiopharmaceuticals. It also discusses anti-tumor immune responses, the induction of inflammatory cell death, alpha particle-cell membrane interactions, and the bystander effect. Dosimetry aspects were not covered in this review.</div></div>","PeriodicalId":19363,"journal":{"name":"Nuclear medicine and biology","volume":"146 ","pages":"Article 109044"},"PeriodicalIF":3.6,"publicationDate":"2025-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144331205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}